National Institutes of Health

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

Civatech Oncology is a medical device company based in Durham, North Carolina, that specializes in developing polymer-based devices for the treatment of cancer through localized low-dose-rate radiation. Founded in 2006, the company focuses on creating devices tailored for specific tumor types, utilizing its patented technology to manufacture them in various shapes and formats. Its flagship product, the CivaString, has received FDA 510k clearance for the treatment of any solid tumor. Civatech's innovative approach aims to enhance the efficacy of brachytherapy for early-stage cancers by reducing procedure times, ensuring uniform dose distribution, and minimizing patient trauma.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

Wake Forest University, founded in 1834, is a respected private institution in the United States known for its strong academic reputation and rigorous liberal arts curriculum. As a non-profit organization, it is dedicated to personal education, fostering inquiry and exploration, and promoting service among its students. The university offers a range of undergraduate and graduate programs across various disciplines, emphasizing a holistic approach to education. Its investment portfolio reflects a commitment to financial stewardship, with a diverse allocation that includes absolute return strategies, fixed income, and public equity, among other asset classes. Wake Forest University continues to uphold its mission of providing a comprehensive educational experience that prepares students for meaningful contributions to society.

Wake Forest School of Medicine, located in Winston-Salem, North Carolina, is an esteemed educational institution founded in 1902, focusing on biomedical research and primary care education. The school offers students hands-on experience with patients from the first week of medical school, emphasizing practical training alongside academic learning. With a nationally recognized research program, Wake Forest School of Medicine has secured over $400 million in extramural funding, supporting its mission to advance medical knowledge and care. The institution educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals, preparing them for a range of careers in the medical field.

Cell Microsystems, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, that focuses on developing, manufacturing, and commercializing innovative tools for single-cell biology. Founded in 2010, the company is known for its proprietary CellRaft™ Technology, which allows for the efficient sorting and isolation of single cells under standard culture conditions, preserving their unperturbed phenotypes and high viability. This technology is complemented by an automated imaging platform, enabling real-time selection and tracking of individual cells throughout imaging, collection, and downstream analysis. By facilitating single-cell isolation from small and valuable samples, Cell Microsystems provides scalable solutions that make advanced cell separation technology accessible to laboratories, enhancing the capabilities of researchers in single-cell research and genomics.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

DILIsym Services, Inc. specializes in the development of drug-induced liver injury (DILI) simulation software for the pharmaceutical industry, with its flagship product, DILIsym, designed to create predictive models of DILI. This software supports liver safety assessments during clinical drug development, facilitating in vitro to in vivo extrapolation, translating preclinical data into clinical trial designs, and assessing the effects of patient variability on hepatotoxicity predictions. DILIsym includes specialized modules for mitochondrial toxicity, innate immunity, and bile acids. The company also offers NAFLDsym, a tool for evaluating treatments for non-alcoholic fatty liver diseases, as well as consulting services related to its software. Founded in 2015 and based in Research Triangle Park, North Carolina, DILIsym Services originated from the Hamner Institutes, acquiring comprehensive intellectual property and materials for its software. As of 2017, it operates as a subsidiary of Simulations Plus, Inc.

Perfusio is a medical device company based in Greenville, North Carolina, specializing in innovative surgical imaging technology. Founded in 2014, the company has developed the Certes system, which provides non-invasive, real-time visualization of blood flow and tissue perfusion during surgeries. This FDA-cleared device enables surgeons to monitor blood flow and assess tissue integrity, allowing them to make informed decisions at critical moments. By visualizing patient hemoglobin flows, Perfusio's technology helps identify and address potential complications during procedures, ultimately leading to improved clinical outcomes for patients. The focus on real-time imaging not only enhances surgical precision but also aims to reduce hospital costs and patient discomfort by minimizing the need for repeat surgeries.

Diabetic Health, Inc. is a medical device company based in Research Triangle Park, North Carolina, specializing in the development of sensors and point-of-care devices aimed at managing critical health conditions, particularly diabetes and severe acute diseases like sepsis. Established in 2009 and formerly known as Clinical Sensors, Inc., the company focuses on harnessing the biological activity of nitric oxide to enhance the performance of continuous glucose monitoring sensors and insulin infusion sets. These innovations aim to mitigate the foreign body response and improve patient outcomes by allowing healthcare providers to better control blood glucose levels and reduce the risk of severe complications. Diabetic Health operates as a subsidiary of KNOW Bio, LLC, following its acquisition in December 2019. With significant funding from NIH and state awards, the company continues to advance its technology to support minimally trained clinical staff in critical care environments.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

NeuroCog Trials (NCT) is a cognition and clinical assessment services company devoted exclusively to applying rigorous standards for key endpoints in multi-site clinical trials. Founded in 2005, NeuroCog Trials is a privately held, certified woman-owned business, headquartered in Durham, North Carolina. There are currently 110 Durham based and 50+ international employees and local language experts.

Zenalux Biomedical is a start-up based in Research Triangle Park, North Carolina, specializing in biomedical diagnostics through advanced biophotonics. With strong connections to Duke University, the company has developed a management team with significant executive experience. Zenalux aims to simplify optical spectroscopy for medical practitioners, enabling real-time, non-destructive diagnostics of biological tissues. Their innovative products translate ultraviolet-visible tissue spectra into quantified biological endpoints, allowing medical professionals to concentrate on practical applications of the technology in clinical settings.

BioMedomics, Inc. is a clinical diagnostics company based in North Carolina that specializes in manufacturing point-of-care and laboratory testing products. Established in 2006, the company offers a range of diagnostic tools, including Sickle SCAN for sickle cell disease, Fungi SCAN for fungal infections, and COVID-19 IgM/IgG Rapid Tests for coronavirus detection. Additionally, BioMedomics produces women's health products like Femi SCAN, which aids in diagnosing vaginal infections. The company also provides contract assay services for various applications, including cell proliferation and cytotoxicity, and develops advanced technologies for analyzing cell-based assays. By delivering immunologically-based tests and sensitive quantitative platforms, BioMedomics aims to enhance disease detection and improve patient outcomes.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.